Nattokinase and Eliquis drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Nattokinase (nattokinase) and Eliquis (apixaban). Common drug interactions include colitis among females and weight increased among males.

The phase IV clinical study analyzes what interactions people have when they take Nattokinase and Eliquis. It is created by eHealthMe based on reports of 21 people who take the same drugs from the FDA, and is updated regularly.

What is Nattokinase?

Nattokinase has active ingredients of nattokinase. It is often used in blood clots. eHealthMe is studying from 227 Nattokinase users. Check the latest studies of Nattokinase.

What is Eliquis?

Eliquis has active ingredients of apixaban. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 191,864 Eliquis users. Check the latest studies of Eliquis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

21 people who take Nattokinase and Eliquis together, and have interactions are studied.

Nattokinase and Eliquis drug interactions.

What are the common drug interactions of Nattokinase and Eliquis, by gender? *:

female:

Colitis (inflammation of colon)
Abdominal distension
Abdominal hernia
Extrasystoles
Hypotension (abnormally low blood pressure)
Weight decreased

male:

Weight increased
Cardiac arrest
Pain
Rash pruritic (redness with itching)
Anxiety
Asthenia (weakness)
Blindness unilateral
Cardiac failure chronic
Cardiac failure congestive
Carotid artery occlusion (artery blockage)

What are the common drug interactions of Nattokinase and Eliquis, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Cardiac arrest
Dyspnoea (difficult or laboured respiration)
Gastrointestinal inflammation (inflammation of stomach and intestine)
Increased appetite
Muscle rupture (tear in muscle)
Sepsis (a severe blood infection that can lead to organ failure and death)
Thrombosis (formation of a blood clot inside a blood vessel)
Vision blurred
Weight increased

50-59:

n/a

60+:

Colitis (inflammation of colon)
Anxiety
Mobility decreased (ability to move is reduced)
Nerve injury
Neuropathy peripheral (surface nerve damage)
Pain
Paraplegia (paralysis of the legs and lower body)
Pruritus (severe itching of the skin)
Pulmonary thrombosis (scarring in the lungs)
Rash

What are the existing conditions these people have? *

Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 6 people, 28.57%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 2 people, 9.52%
Hyperglycemia (high blood sugar): 2 people, 9.52%
Cushing's Syndrome (obesity, a rounded face, increased fat): 2 people, 9.52%

* Approximation only. Some reports may have incomplete information.

Do you take Nattokinase and Eliquis?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously